on INNATE PHARMA (EPA:IPH)
Innate Pharma Releases Initial Phase 1 Data for IPH4502 at ENA 2026
Innate Pharma has announced encouraging initial findings from its Phase 1 study of IPH4502, a Nectin-4-targeting antibody-drug conjugate. The data, shared at the 38th EORTC-NCI-AACR Symposium, highlights a favorable tolerability profile, with stomatitis as the only dose-limiting toxicity. Low hematologic toxicity suggests stable linker stability.
Antitumor activity was noted across various tumor types, with a 33% objective response rate at the maximum tolerated dose in non-urothelial tumors. Moving forward, the company plans dose optimization in 2027, aiming to refine the dosage for future Phase 2 trials.
An in-person and virtual Key Opinion Leader event followed the presentation. Innate remains focused on meeting unmet needs in urothelial cancer treatment.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news